

# AM630

Catalog No: tcsc0854



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

164178-33-0

**Formula:**

$C_{23}H_{25}IN_2O_3$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

504.36

## Product Description


AM630 is a selective **CB<sub>2</sub>** antagonist with **K<sub>i</sub>** of 31.2 nM, and displays 165-fold selectivity over CB<sub>1</sub> receptors.

IC<sub>50</sub> & Target: Ki: 31.2 nM (CB<sub>2</sub>)

***In Vitro:***

The AM251 and AM630-evoked  $\text{Ca}^{2+}$  influxes into TG sensory neurons are concentration-dependent, and fitted. The  $\text{EC}_{50}$  for AM251 and AM630 are 7.37  $\mu\text{M}$  and 15.6  $\mu\text{M}$ , respectively. AM251 and AM630 activate TRPA1 in TG sensory neurons. AM630 is comparable in value in both TRPA1 and TRPV1/TRPA1 expressing CHO cells (2 and 4.6  $\mu\text{M}$ , respectively). AM251 and AM630 activation of TRPA1 is modulated by TRPV1<sup>[2]</sup>. AM630 (0, 50, 100, and 200 nM) is not toxic to RAW264.7 cells. AM630 (100 nM) substantially inhibits osteoclastogenesis in cultures with RANKL and Ti particles in a dose-dependent manner<sup>[3]</sup>. AM630 (1  $\mu\text{M}$ ) blocks the CP-55,940 dose response with  $\text{EC}_{50}$  of 170 nM at human and  $\text{EC}_{50}$  of 110 nM at rat cannabinoid CB2 receptor<sup>[4]</sup>.

***In Vivo:*** AM630 (2, 3 mg/kg, i.p.) significantly reduces the time spent in the light box compared with vehicle group. AM630 increases anxiety since the time spent in the light box is reduced compared with its corresponding control group. AM630 (1, 2 or 3 mg/kg, i.p., twice a day) produces a significant anxiolytic effect, increasing the time spent in the light box at all of the doses used<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!